XXXX in pregnancy--treatment with @entity4235 .

@entity1 @entity4235 @entity10586 @entity699 @entity619 @entity701 @entity652
A 23-year-old female presented with severe @entity699 in the 23rd week of pregnancy. Investigations showed plasma @entity701 770 nmol/l (08.00 h) and 850 nmol/l (23.00 h); plasma ACTH was 10 ng/l (08.00 h) and 27 ng/l (23.00 h); urinary free @entity701 excretion was 2460 nmol/24 h. @entity619 2 mg 6-hourly for 48 h suppressed the 08.00 h plasma @entity701 only to 680 nmol/l. Abdominal C.T. scan showed a right @entity652 . The @entity1 was treated with @entity4235 and a good clinical improvement ensued. Plasma @entity701 was reduced to 300-500 nmol/l. Depsite ultrasonographic evidence of normal fetal growth, urinary @entity10586 excretion was markedly deficient. Prior to the spontaneous onset of labour, there was a marked rise in plasma @entity701 despite continuous @entity4235 treatment. A normal female @entity1 was born at 37 weeks' gestation. The maternal @entity652 was subsequently removed. The deficiency of @entity10586 synthesis during the pregnancy may be explained by @entity4235 -induced inhibition of C19-hydroxylation.
